1 – 8 of 8
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia
(
- Contribution to journal › Article
- 2015
-
Mark
Satisfactory outcome after intensive chemotherapy with pragmatic use of minimal residual disease (MRD) monitoring in older patients with Philadelphia-negative B cell precursor acute lymphoblastic leukaemia: a Swedish registry-based study
(
- Contribution to journal › Article
- 2014
-
Mark
Outcome after HSCT in Philadelphia chromosome positive acute lymphoblastic leukemia in Sweden: a population-based study
(
- Contribution to journal › Article
-
Mark
Cladribine prolongs progression-free survival and time to second treatment compared to fludarabine and high-dose chlorambucil in chronic lymphocytic
(
- Contribution to journal › Article
- 2011
-
Mark
Hematopoietic stem cell transplantation rates and long-term survival in acute myeloid and lymphoblastic leukemia: Real-World Population-Based Data From the Swedish Acute Leukemia Registry 1997-2006.
(
- Contribution to journal › Article
-
Mark
t(9;11)(p22;p15) [NUP98/PSIP1] is a poor prognostic marker associated with de novo acute myeloid leukaemia expressing both mature and immature surface antigens.
(
- Contribution to journal › Letter
- 2008
-
Mark
The BCL-2 promoter (-938C > A) polymorphism does not predict clinical outcome in chronic lymphocytic leukemia
(
- Contribution to journal › Article
-
Mark
The GNAS1 T393C polymorphism and lack of clinical prognostic value in chronic lymphocytic leukemia
(
- Contribution to journal › Article